Lu et al. [111] showed that treatment with TKI reduces the percentage of T, Treg, CD4+, and CD8+ T cells to a different extent depending on the TKI used in CML patients compared to healthy controls. The gene discussed is CD4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.